Limits...
Brentuximab vedotin.

- Drugs R D (2011)

Bottom Line: Brentuximab vedotin (cAC10-vcMMAE; SGN 35; SGN-35) is an anticancer antibody-drug conjugate under development by Seattle Genetics Inc. and its licensee Millennium: The Takeda Oncology Company.It comprises the anti-CD30 monoclonal antibody cAC10 conjugated to the cytotoxic agent monomethyl auristatin E, a synthetic analog of the tubulin polymerization inhibitor dolastatin 10.It is under investigation for use in Hodgkin lymphoma and non-Hodgkin lymphoma (specifically anaplastic large cell lymphoma) in North America and Europe.

View Article: PubMed Central - PubMed

ABSTRACT
Brentuximab vedotin (cAC10-vcMMAE; SGN 35; SGN-35) is an anticancer antibody-drug conjugate under development by Seattle Genetics Inc. and its licensee Millennium: The Takeda Oncology Company. It comprises the anti-CD30 monoclonal antibody cAC10 conjugated to the cytotoxic agent monomethyl auristatin E, a synthetic analog of the tubulin polymerization inhibitor dolastatin 10. It is under investigation for use in Hodgkin lymphoma and non-Hodgkin lymphoma (specifically anaplastic large cell lymphoma) in North America and Europe. This review discusses the key development milestones and therapeutic trials of this drug.

Show MeSH

Related in: MedlinePlus

History
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3585690&req=5

Tab2: History


Brentuximab vedotin.

- Drugs R D (2011)

History
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3585690&req=5

Tab2: History
Bottom Line: Brentuximab vedotin (cAC10-vcMMAE; SGN 35; SGN-35) is an anticancer antibody-drug conjugate under development by Seattle Genetics Inc. and its licensee Millennium: The Takeda Oncology Company.It comprises the anti-CD30 monoclonal antibody cAC10 conjugated to the cytotoxic agent monomethyl auristatin E, a synthetic analog of the tubulin polymerization inhibitor dolastatin 10.It is under investigation for use in Hodgkin lymphoma and non-Hodgkin lymphoma (specifically anaplastic large cell lymphoma) in North America and Europe.

View Article: PubMed Central - PubMed

ABSTRACT
Brentuximab vedotin (cAC10-vcMMAE; SGN 35; SGN-35) is an anticancer antibody-drug conjugate under development by Seattle Genetics Inc. and its licensee Millennium: The Takeda Oncology Company. It comprises the anti-CD30 monoclonal antibody cAC10 conjugated to the cytotoxic agent monomethyl auristatin E, a synthetic analog of the tubulin polymerization inhibitor dolastatin 10. It is under investigation for use in Hodgkin lymphoma and non-Hodgkin lymphoma (specifically anaplastic large cell lymphoma) in North America and Europe. This review discusses the key development milestones and therapeutic trials of this drug.

Show MeSH
Related in: MedlinePlus